Up-regulation of type I collagen during tumorigenesis of colorectal cancer revealed by quantitative proteomic analysis

Zou, Xia; Feng, Bo; Dong, Taotao; Yan, Guoquan; Tan, Binbin; Shen, Hao; Huang, Ao; Zhang, Xiu; Zhang, Menghui; Yang, Pengyuan; Zheng, Min; Zhang, Yan

doi:10.1016/j.jprot.2013.10.020

Cited by 92 publications

(95 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These findings are in agreement with those reported by other independent studies, albeit from other epithelial tumors in some instances. One study using quantitative proteomic analysis found elevated levels of collagen I in both the tissue and serum of patients with colorectal cancer (Zou et al, 2013). In another study, an elevated serum level of CEA (CEACAM5) was associated with survival of patients with PaCa (Tas et al, 2013).…”

Section: Discussionmentioning

confidence: 99%

Retraction: “Identification of Novel Biomarkers for Pancreatic Cancer Using Integrated Transcriptomics With Functional Pathways Analysis” by Zhang, X., Tong, P., Chen, J., Pei, Z., Zhang, X., Chen, W., Xu, J. and Wang, J.

Zhang

Tong

Chen

et al. 2016

Journal Cellular Physiology

View full text Add to dashboard Cite

The above article from the Journal of Cellular Physiology, published online on 10 March 2016 in Wiley Online Library as Early View (http://onlinelibrary.wiley.com/enhanced/doi/10.1002/jcp.25353/), has been retracted by agreement between Gary Stein, the journal's Editor-in-Chief, and Wiley Periodicals, Inc. The retraction has been agreed following an investigation at the University of Texas, MD Anderson Cancer Center, which confirmed that the article was submitted and approved for publication by Dr. Jin Wang without acknowledgement of NIH funding received or the consent and authorship of Dr. Ann Killary and Dr. Subrata Sen, with whom the manuscript was originally drafted.

show abstract

Section: Discussionmentioning

confidence: 99%

Retraction: “Identification of Novel Biomarkers for Pancreatic Cancer Using Integrated Transcriptomics With Functional Pathways Analysis” by Zhang, X., Tong, P., Chen, J., Pei, Z., Zhang, X., Chen, W., Xu, J. and Wang, J.

Zhang

Tong

Chen

et al. 2016

Journal Cellular Physiology

View full text Add to dashboard Cite

show abstract

“…On one hand, frequent promoter methylation of COL1A1 was detected in renal cell carcinoma and hepatocellular carcinoma [9, 10], and COL1A2 was downregulated in melanoma [11], head and neck cancer [14], and bladder cancer [15]. On the other hand, COL1A1 and COL1A2 mRNA was upregulated in colorectal cancer and medulloblastoma [16, 17]. Consistent with previous reports [12, 18, 19], the present study demonstrated that COL1A1 and COL1A2 mRNA expression levels were highly expressed in gastric cancer specimens compared to normal gastric epithelium by real-time quantitative PCR analysis.…”

Section: Discussionmentioning

confidence: 99%

Identification of COL1A1 and COL1A2 as candidate prognostic factors in gastric cancer

2016

View full text Add to dashboard Cite

BackgroundThe role of type I collagen, composed of collagen type I alpha 1 (COL1A1) and collagen type I alpha 2 (COL1A2), has been studied in several cancers. However, the expression of COL1A1 and COL1A2 in malignant, premalignant, and normal gastric tissues and their clinical significances in gastric cancer have not been elucidated.MethodsReal-time quantitative PCR was performed in 55 malignant, 27 premalignant, and 19 normal tissues to measure COL1A1 and COL1A2 messenger RNA (mRNA) expression, and the correlations between COL1A1 and COL1A2 expression and clinicopathological parameters and patients’ survival rate were analyzed.ResultsWe found that COL1A1 mRNA expression was significantly upregulated in premalignant and malignant tissues than in normal tissues, whereas COL1A2 mRNA expression was significantly higher in malignant tissues than in premalignant and normal tissues. Moreover, COL1A1 expression was unrelated to clinicopathological parameters, while COL1A2 expression was positively related to tumor size and depth of invasion. Besides, higher COL1A1 and COL1A2 expression levels were related to lower overall survival.ConclusionsWe find that COL1A1 might have its potential as a monitoring factor to screen early gastric cancer, and COL1A1 and COL1A2 might predict poor clinical outcomes in gastric cancer patients.

show abstract

“…unlikely that the isolated biologic properties of Arresten are overshadowed by other processes such as continuous matrix degradation and tissue remodeling. Type I collagen has also been shown to play a role in colorectal cancer carcinogenesis as the degraded telopeptide of type I collagen was correlated to the presence of colorectal cancer and also associated with stage and prognosis (36,37). The biologic role of the overall collagen composition and metabolism in the tumor microenvironment is a relatively new research field which is gaining further focus, due to these recent interesting findings.…”

Section: Nonmalignant Epithelium Invasive Frontmentioning

confidence: 99%

The Prognostic and Predictive Value of Soluble Type IV Collagen in Colorectal Cancer: A Retrospective Multicenter Study

Rolff

Christensen

Vainer

et al. 2016

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: To investigate the prognostic and predictive biomarker value of type IV collagen in colorectal cancer.Experimental Design: Retrospective evaluation of two independent cohorts of patients with colorectal cancer included prospectively in 2004-2005 (training set) and 2006-2008 (validation set). Plasma samples were available from 297 (training set) and 482 (validation set) patients. Type IV collagen determinations were performed using an ELISA. From the training set, 222 tumors were available for IHC. Clinical and follow-up data were retrieved from patient files and national registries.Results: High levels of type IV collagen showed independent prognostic significance in both cohorts with hazard ratios (HRs; for a one-unit change on the log base 2 scale) of 2.25 [95% confidence intervals (CIs), 1.78-2.84; P < 0.0001] and 2.24 (95% CI, 1.75-2.86; P < 0.0001) for the training and validation set, respectively. The prognostic impact was present both in patients with metastatic and nonmetastatic disease. The predictive value of the marker was investigated in stage II and III patients. In the training set, type IV collagen was prognostic both in the subsets of patients receiving and not receiving adjuvant antineoplastic therapy. However, in the validation set, the prognostic effect of the marker vanished when looking at patients who received adjuvant antineoplatic therapy (HR 0.90; 95% CI, 0.42-1.93) but was still present in the group not receiving adjuvant chemotherapy (HR 2.88; 95% CI, 1.98-4.21).Conclusions: The results indicate clinical validity of type IV collagen as a prognostic biomarker in colorectal cancer, although the suggested predictive role of the marker should be validated.

show abstract

Up-regulation of type I collagen during tumorigenesis of colorectal cancer revealed by quantitative proteomic analysis

Cited by 92 publications

References 52 publications

Retraction: “Identification of Novel Biomarkers for Pancreatic Cancer Using Integrated Transcriptomics With Functional Pathways Analysis” by Zhang, X., Tong, P., Chen, J., Pei, Z., Zhang, X., Chen, W., Xu, J. and Wang, J.

Retraction: “Identification of Novel Biomarkers for Pancreatic Cancer Using Integrated Transcriptomics With Functional Pathways Analysis” by Zhang, X., Tong, P., Chen, J., Pei, Z., Zhang, X., Chen, W., Xu, J. and Wang, J.

Identification of COL1A1 and COL1A2 as candidate prognostic factors in gastric cancer

The Prognostic and Predictive Value of Soluble Type IV Collagen in Colorectal Cancer: A Retrospective Multicenter Study

Contact Info

Product

Resources

About